Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids
US6814964B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 25, 2002 |
| Grant date | Nov 9, 2004 |
| Priority date | — |
| Expiry date | Jul 6, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/907
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector molecule covalently joined to a second nucleic acid, wherein the second nucleic acid has a region of at least partial complementarity to the first nucleic acid, wherein the first nucleic acid is in a base pairing relationship with the second nucleic acid and the first or second effector molecules are proteins, polypeptides, lipids or sugars. The supramolecule may further have a third supramolecule component which includes a third effector molecule covalently joined to a third nucleic acid, wherein the third nucleic acid has a region of at least partial complementary to the first nucleic acid or the second nucleic acid and wherein the third nucleic acid is in a base pairing relationship with the second nucleic acid or the first nucleic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.